A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.

The Rapid RCT Lab has worked with 16 departments across NYU Langone and completed 47 trials, and we are currently involved in ...

‘A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial’ by David Erritzoe et al. was published in Nature Medicine at 16:00 UK time on ...

More cases of colorectal cancer are detected at an early stage with screening. This is according to new research based on data from over 278,000 60-year-olds, who were randomly selected to undergo one ...

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...

Randomized, blinded clinical study evaluating injectable autologous hair follicle secretome in patients with androgenic ...

A randomized controlled study found that time-restricted feeding—a form of intermittent fasting—significantly reduced ...

GRAIL's topline results from the NHS-Galleri trial were a clear disappointment with no major implications on ...

The Rapid RCT Lab is a nationally-leading team conducting innovative, rapid RCTs to improve the delivery of services at the ...